2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1058

Doxycycline Directly Scavenges Reactive Oxygen Species and Inhibits the Formation of Malondialdehyde-Acetaldehyde-Protein Adducts – a Novel Mechanism of Action for an Old Drug
Abstract Number: 1259

Driving Performance and Safety in Rheumatoid Arthritis: A Systematic Review
Abstract Number: 2605

Drug Retention and Response Rates of TNFi Treatment in 13,170 Patients with Psoriatic Arthritis Treated in Routine Care – Pooled Data from the Eurospa Research Network Collaboration
Abstract Number: 1867

Drug Retention and Response Rates of TNFi Treatment in 21,470 Patients with Axial Spondyloarthritis Treated in Clinical Practice– Pooled Data from the Eurospa Research Network Collaboration
Abstract Number: 2618

Drug Survival of Non TNF Inhibitors Bdmards in Psoriatic Arthritis (Ustekinumab/Secukinumab) : A Real-Word Multicentric Cohort of 161 Patients
Abstract Number: 552

Drug Tolerability and Discontinuation Reasons of 7 Biologics in 4466 Treatment Courses of Rheumatoid Arthritis -the Answer Cohort Study-
Abstract Number: L17

Dual Neutralization of IL-17A and IL-17F with Bimekizumab in Patients with Active Psa: Results from a 48-Week Phase 2b, Randomized, Double‑Blind, Placebo-Controlled, Dose-Ranging Study
Abstract Number: 1275

Dual-Energy CT for the Diagnosis of Gout: A Prospective Study in Patients with No Prior History of Gout
Abstract Number: 2942

Dyadic Study of Partner Social Support for Physical Activity and Its Role in the Initiation and Maintenance of Increased Physical Activity Among Insufficiently Active People with Hip/Knee Osteoarthritis
Abstract Number: 2002

Dynamic Compression of Articular Cartilage Explants Increases Formation and Decreases Degradation of Type II Collagen
Abstract Number: 304

Dynamic MRI in Rheumatoid Arthritis for the Assessment of Synovitis Promoting Cartilage Loss
Abstract Number: 2777

Dynamics in Peripheral Blood Cell Counts in Giant Cell Arteritis before Treatment, during Treatment and in Treatment-Free Remission
Abstract Number: 1974

Dynamics of Transcriptional Signatures from Synovial Macrophage Subsets during Acute and Chronic Murine Models of Inflammatory Arthritis
Abstract Number: 2079

Dysbiosis of Gut Microbiomes in Ankylosing Spondylitis
Abstract Number: 2067

Dysbiosis-Dependent Inflammasomes Activation Drives Innate Immune Responses in Ankylosing Spondylitis Patients

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].